CagrilintideCheck methods and identity
The trials designed to test cagrilintide on its own
3 numbered sourcesSource years 2025, 2026
Peptides are short chains of amino acids joined by peptide bonds. Some mimic hormones that carry information about nutrients and fullness. Cagrilintide is an investigational, long-acting peptide that activates receptors for amylin and calcitonin. It is often discussed alongside semaglutide because they are being studied together as CagriSema. Several registry records updated in 2026 show how researchers are studying cagrilintide separately. [1, 2, 3]
Two trials called RENEW compare cagrilintide with placebo over a 64-week treatment period. One enrolls people with excess body weight, and the other specifically enrolls people who also have type 2 diabetes. Both use relative change in body weight as a primary measure. By putting the studies in different populations, researchers can examine outcomes in people whose underlying metabolic conditions and background care may differ. The records identify the assigned interventions and the planned measurements. [2, 3]
A separate study first posted in August 2026 compares two presentations of cagrilintide with placebo. Its primary weight measurement is planned for 26 weeks. A comparison of presentations can help determine whether preparations intended to deliver the same active peptide have comparable observed effects under the trial conditions. That is a narrower question than how one active ingredient compares with a drug that acts on another receptor. [1]
The entries available by November 8, 2026 list no posted results for these three studies. They show that the research program includes placebo-controlled tests of cagrilintide itself and a comparison of its presentations. Estimates of benefit and adverse events will depend on actual outcomes in the participants and how completely investigators are able to report them. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
